Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC
The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity
Act With Humanity
March 9 marks the devastating anniversary of the day my stepson Max died after a three-year battle with cancer. Max was 17 years old. I have dedicated most of the last 34 years to galvanizing the global community to help families avoid the suffering of the premature loss of their loved one. In the process, a thriving global network of people helping people emerged as a beacon of hope and light. The work we do at The Max Foundation elevates the common humanity and interconnectedness among all of us, no matter where we live. We are one, we long for the same, we need each other.
This year, March 9 finds us navigating difficult times yet unwilling to accept a global current that wants to convince us to focus on ourselves and ignore those most vulnerable among us.
While trying to find my footing, a news article published recently resonated with me and reminded me that our capacity to act with humanity is still intact. Today my feelings can be summarized in one short message: this is not the time to be a goldfish. I invite you to read my editorial, published in Devex, and share widely.
Pat Garcia-Gonzalez is the CEO of The Max Foundation. Under Pat’s direction The Max Foundation is dedicated to accelerating health equity by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those who no one else is helping. Pat lives in Edmonds, Washington, where she raised her four sons.
Related Articles
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….
The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….